Compare KTB & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KTB | AKRO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.5B |
| IPO Year | N/A | 2019 |
| Metric | KTB | AKRO |
|---|---|---|
| Price | $76.25 | $54.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $96.38 | $73.56 |
| AVG Volume (30 Days) | 550.9K | ★ 1.7M |
| Earning Date | 11-03-2025 | 11-07-2025 |
| Dividend Yield | ★ 2.78% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.88 | N/A |
| Revenue | ★ $2,833,659,000.00 | N/A |
| Revenue This Year | $20.46 | N/A |
| Revenue Next Year | $11.11 | N/A |
| P/E Ratio | $19.64 | ★ N/A |
| Revenue Growth | ★ 9.91 | N/A |
| 52 Week Low | $50.00 | $21.34 |
| 52 Week High | $96.80 | $58.40 |
| Indicator | KTB | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 53.32 | 66.54 |
| Support Level | $71.85 | $54.22 |
| Resistance Level | $78.28 | $54.70 |
| Average True Range (ATR) | 2.34 | 0.14 |
| MACD | 0.89 | -0.11 |
| Stochastic Oscillator | 78.58 | 64.18 |
Kontoor Brands Inc is a lifestyle apparel company. It is engaged in designing, manufacturing, sourcing, marketing, and distribution of its portfolio of brands, including Wrangler and Lee. It manufactures its products in owned and leased facilities and distributes the products through both brick-and-mortar and e-commerce retailers. The Company has two reportable segments: Wrangler and Lee. It generates the majority of its revenue from the Wrangler segment. The company's geographical segments are the United States and International, of which the majority of its revenue comes from the United States.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.